Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C Reduction

NCT04992065 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04992065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04992065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C Reduction
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
August 3, 2021
Completion date
June 20, 2022
Enrollment
267 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease